TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY (TAPESTRY)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04481256 |
Recruitment Status :
Recruiting
First Posted : July 22, 2020
Last Update Posted : January 20, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carcinoma, Squamous Cell Oesophageal Cancer | Radiation: External beam radiotherapy Drug: Bintrafusp alfa Drug: Paclitaxel Drug: Carboplatin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 49 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY |
Actual Study Start Date : | November 11, 2020 |
Estimated Primary Completion Date : | June 1, 2023 |
Estimated Study Completion Date : | June 1, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy
Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy |
Radiation: External beam radiotherapy
External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy Drug: Bintrafusp alfa Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. Drug: Paclitaxel Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Drug: Carboplatin Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. |
- Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa [ Time Frame: 36 months ]The primary outcome of this study is the percentage of patients that completes at least two cycles of bintrafusp alfa together with their chemoradiotherapy regimen.
- Incidence and severity of toxicity [ Time Frame: 36 months ]Incidence and severity of toxicity defined according to CTCAE v5 and and Radiation Oncology Group (RTOG) criteria.
- Percentage completion [ Time Frame: 36 months ]Percentage completion of chemotherapy and radiation treatment
- Percentage withdrawal rate [ Time Frame: 36 months ]Percentage withdrawal rate from chemoradiation due to bintrafusp alfa related complications
- locoregional progression [ Time Frame: 36 months ]Infield locoregional progression free survival
- progression [ Time Frame: 36 months ]Any progression free survival
- Survival [ Time Frame: 36 months ]Overall survival
- Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ C30)) [ Time Frame: 36 months ]Overall Quality of life ranging from 0-100 with 100 being best Quality of Life with special focus on dysphagia
- adverse events [ Time Frame: 36 months ]To determine the number and grade of adverse events of bintrafusp alfa combined with chemoradiotherapy according to NCI common toxicity criteria (CTC) version 5
- Biomarker [ Time Frame: 54 months ]To perform exploratory biomarker analyses for treatment response

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven squamous cell carcinoma of the esophagus or gastro esophageal junction.
- Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients with M1 disease solely on the basis of supraclavicular metastasis are eligible. Patients with resectable tumors refusing radical surgery are eligible.
- Locoregional recurrences without distant metastasis after surgery alone or endoscopical resection
- Locoregional recurrences without distant metastasis after neoadjuvant chemoradiation + resection or definitive chemoradiation outside the previously irradiated area, provided that full dose of radiation can safely be delivered.
- Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible if all other criteria are fulfilled.
- If the tumor extends below the gastroesophageal (GE) junction into the proximal stomach, the bulk of the tumor must involve the esophagus or GE junction.
- Age ≥ 18.
- ECOG performance status 0-2 (cf. Appendix A).
-
Adequate hematological, renal and hepatic functions defined as:
- Neutrophils ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Hemoglobin ≥ 5.6 mmol
- Total bilirubin ≤ 1.5 x upper normal limit
- ASAT and ALAT ≤ 1.5 x upper normal limit, Alkaline Phosphatase ≤ 2.5 x upper normal limit.
- PT (INR) ≤ 1.5 x upper normal limit and aPTT ≤ 1.5 x upper normal limit.
- Creatinine clearance (Cockroft) > 60 ml/min
- Written, voluntary informed consent
- Patients must be accessible to management and follow-up in the treatment center
Exclusion Criteria:
- Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer.
- Patient with tracheo-esophageal fistula or extension into the mucosal layer of the trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is allowed, but not through the trachea.
- Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus level.
- Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
- Patient (male or female) in the reproductive age is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
- Previous chemotherapy, radiation and/or treatment with checkpoint inhibitors for the currently present esophageal tumor.
- Previous chemotherapy and/or treatment with targeted agents and/or checkpoint inhibitors for other forms of cancer within the last six months.
- Previous radiation to the mediastinum precluding full dose radiation of the currently present esophageal tumor.
- Persisting grade >1 NCI CTCAE 5.0 toxicity (except alopecia and vitiligo) related to prior therapy; however, grade ≤2 sensory neuropathy is acceptable.
- Presence of an esophageal stent.
- History of bleeding diathesis or major bleeding event (grade ≥ 2) in the month prior to first dose of trial treatment.
- Clinically significant cardiovascular disease precluding safe treatment with chemoradiation.
- Evidence of pulmonary fibrosis and/or clinically significant impairment of lung function precluding safe treatment with chemoradiation. In case of doubt about pulmonary function, a lung function test should be performed and, in case of abnormalities, discussed with the principle investigator.
- Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing cremophor, such as teniposide or cyclosporine.
- Mental status that would prohibit the understanding and giving of informed consent.
- Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or tube feeding.
- Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine for patients with a history of autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo with dermatological manifestations only are eligible to enter the study.
- A diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Diagnosis of HIV unless stable on antiretroviral therapy for at least 4 weeks, no evidence of multi-drug resistance, viral load of < 400 copies/ml and CD4+ T-cells ≥ 350 cells/µl.
- Active HBV/HCV. Participants on a stable dose of antiviral therapy with HBV/HCV viral load below the limit of quantification are eligible.
- Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- An active infection requiring systemic therapy, which has not resolved 3 days (simple infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior to the first dose of trial treatment.
- Administration of a live vaccine within 30 days prior to the first dose of trial treatment. Seasonal flu vaccines that do not contain a live virus are permitted.
- Patients with prior allogeneic stem cell or solid organ transplantation.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04481256
Contact: Linde Veen | 020-5665955 | l.veen1@amsterdamumc.nl | |
Contact: Hanneke WM van Laarhoven, MD, PhD | 020-5665955 | h.vanlaarhoven@amsterdamumc.nl |
Netherlands | |
Academic Medical Center, Medical Oncology | Recruiting |
Amsterdam, Netherlands, 1100 DD | |
Contact: H WM van Laarhoven, MD, PhD, PhD 31 20 5665955 h.vanlaarhoven@amc.uva.nl | |
Contact: Lyda ter Hofstede 31 20 5668229 trialmedonc@amc.uva.nl | |
Principal Investigator: H. WM van Laarhoven, MD, PhD, PhD |
Principal Investigator: | Hanneke WM van Laarhoven, MD,PhD | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Responsible Party: | H.W.M. van Laarhoven, Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
ClinicalTrials.gov Identifier: | NCT04481256 |
Other Study ID Numbers: |
73750 |
First Posted: | July 22, 2020 Key Record Dates |
Last Update Posted: | January 20, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Definitive chemoradiation TGF-beta inhibition PDL-1 ihibition feasability |
Carcinoma Carcinoma, Squamous Cell Esophageal Squamous Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Head and Neck Neoplasms |
Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Paclitaxel Carboplatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |